Loading
A phase 1/2 trial of ipilimumab, nivolumab and nogapendekin alfa inbakicept in lung cancer, run by Washington University School of Medicine, now recruiting.
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07355205 by Washington University School of Medicine, with a registry enrolment figure of 26 participants, started 2026-07-07 and due to reach its primary completion in 2032-07-31. Interventions recorded: Ipilimumab; Nivolumab; Nogapendekin alfa inbakicept. Conditions listed: Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent. Primary outcome: Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants); Incidence of dose-limiting toxicities (DLTs) (Phase Ib participants). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed, previously untreated or recurrent metastatic NSCLC". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipilimumab, Lung cancer trials open today (registry snapshot), Nivolumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Ipilimumab, Lung cancer trials open today (registry snapshot), Nivolumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Ipilimumab, Lung cancer trials open today (registry snapshot), Nivolumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Ipilimumab, Lung cancer trials open today (registry snapshot), Nivolumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/